ClinicalTrials.gg
CompletedNCT01214850Updated Apr 21, 2016Results posted

Novartis Vaccine and Diagnostics Carriage Trial

A Phase 3 interventional study of Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ) and MenACWY-CRM conjugate vaccine in N. Meningitidis Carriage, sponsored by Novartis Vaccines. Completed at 10 sites in United Kingdom. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-21.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,968
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Study summary

The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal vaccines on carriage of Neisseria meningitidis in a young adult population.

02

Conditions studied

  • N. Meningitidis Carriage

Keywords

  • Meningococcal vaccines
  • Meningococcal B
  • Meningococcal ACWY serogroups
03

In context

Lead sponsor

Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.

First submitted before Novartis Vaccines left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects, 18-24 years of age who provided written at the time of enrollment;
  • Subjects who were available for all the visits scheduled in the study;
  • Subjects who were in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of any serogroup B meningococcal vaccine administration;
  • Current or previous, confirmed or suspected disease caused by N. meningitidis;
  • Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;
  • Significant acute or chronic infection within the previous 7 days or fever (defined as oral temperature ≥38ºC) within the previous day;
  • Antibiotics within 3 days (72 hours) prior to enrollment;
  • Pregnancy or nursing (breastfeeding) mothers;
  • Females of childbearing age who had not used or did not plan to use acceptable measures, for the 12 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence were considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry;
  • Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; disease, (HIV) infection or acquired immunodeficiency syndrome (AIDS), or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
  • Known or suspected impairment/alteration of the immune system, therapy, including use of in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids within the previous 60 days. [Use of topical corticosteroids administered during the study in limited areas (i.e., eczema on knees or face or elbows) of the body were allowed]; use of immunostimulants;
  • Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
  • History of severe allergic reactions after previous vaccinations or to any vaccine component;
  • Participation in another clinical trial within the last 90 days or planned for during study;
  • Family members and household members of research staff;
  • Any condition which in the opinion of the investigator and/or the Regional MD may interfere with the evaluation of the study objectives.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,968 participants (actual)

Study arms

  • Experimental
    rMenB+OMV

    Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart

    Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)

  • Experimental
    MenACWY

    Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart

    Biological: MenACWY-CRM conjugate vaccine

  • Active comparator
    Control

    Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart

    Biological: Japanese Encephalitis vaccine

Interventions

  • BiologicalMeningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)
  • BiologicalMenACWY-CRM conjugate vaccine
  • BiologicalJapanese Encephalitis vaccine

    Also known as: IXIARO

06

What researchers measure

Primary outcomes

  1. Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination

    Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported. Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.

    Time frame: 61 days (31 days after receiving the second injection)

  2. Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination

    The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

    Time frame: 31 days after MenACWY-CRM injection

Secondary outcomes

  1. Percentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination

    The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  2. Percentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination

    Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  3. Percentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination

    Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  4. Percentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination

    Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  5. Percentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination

    Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  6. Percentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination

    Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported

    Time frame: Up to 361 days after vaccination

  7. Percentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination

    Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  8. Percentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination

    Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  9. Percentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination

    Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  10. Percentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination

    Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  11. Percentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination

    Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  12. Percentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination

    Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  13. Percentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination

    Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  14. Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination

    The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  15. Percentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination

    The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  16. Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination

    The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  17. Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination

    The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  18. Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination

    The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  19. Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination

    The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.

    Time frame: Up to 361 days after vaccination

  20. The Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV

    The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.

    Time frame: Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)

  21. The Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM

    The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.

    Time frame: Any time post vaccination (the date of first observation of the carriage and the date of the last observation of the carriage)

  22. The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine

    The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.

    Time frame: Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)

  23. The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine

    The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.

    Time frame: Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)

  24. Percentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination

    The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported. The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA). H44/76, 5/99 and NZ98/254 are strains in serogroup B.

    Time frame: Up to 361 days after vaccination

  25. Percentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers

    The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.

    Time frame: Up to 12 months after vaccination

  26. Percentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group

    The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.

    Time frame: Up to 361 days after vaccination

  27. The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.

    The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.

    Time frame: Up to 361 days after vaccination

  28. Percentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.

    The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.

    Time frame: Up to 361 days after vaccination

  29. The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.

    The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs. Serogroups A and W were not analysed.

    Time frame: Up to 361 days after vaccination

  30. Percentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.

    The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported. Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer \< 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer. Analysis was not done for serogroups A and W.

    Time frame: 61 days

  31. The hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group

    The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. Analysis was not done for serogroups A and W.

    Time frame: Up to 361 days after vaccination

  32. Percentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.

    The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported. Analysis was not done for serogroups A and W.

    Time frame: Up to 361 days after vaccination

  33. Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group

    The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.

    Time frame: Day 1 through day 7 after any vaccination

07

Results

Posted Jan 23, 2014

Participant flow

Subjects were enrolled from 10 sites in United Kingdom

Participant flow — Overall Study
MilestonerMenB+OMVMenACWYControl
Started979988987
Completed796844826
Not completed183144161
Withdrew: Withdrawal by subject383128
Withdrew: Lost to follow-up12498123
Withdrew: Protocol violation556
Withdrew: Adverse event or death1183
Withdrew: Inappropriate enrollment210
Withdrew: Administrative reason100
Withdrew: Unable to classify211

Outcome measures

PrimaryPercentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination

Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported. Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.

Time frame:
61 days (31 days after receiving the second injection)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline8 (6 to 10)7 (6 to 9)
Month 2 (N= 916, 928)9 (8 to 12)8 (6 to 10)
Statistical analysis
  • rMenB+OMV vs Control · Regression, Logistic · p = 0.3828 · Odds ratio (or): 1.185 · 95% CI 0.809 to 1.737
PrimaryPercentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination

The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

Time frame:
31 days after MenACWY-CRM injection
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline6 (5 to 8)5 (4 to 7)
Month 1 (N=956, 947)6 (5 to 8)6 (5 to 8)
Statistical analysis
  • MenACWY vs Control · Regression, Logistic · Odds ratio (or): 0.840 · 95% CI 0.555 to 1.273
SecondaryPercentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination

The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline9 (8 to 11)9 (7 to 11)
1 month post 1st vaccination (Day 31) N=931, 9479 (7 to 11)9 (7 to 11)
1 month post 2nd vaccination (Day 61) N=916, 92811 (9 to 13)10 (8 to 12)
3 months post 2nd vaccination (Day 121) N=860, 88510 (8 to 12)10 (8 to 12)
5 months post 2nd vaccination (Day 181) N=832, 8649 (8 to 12)10 (8 to 12)
11 months post 2nd vaccination (Day 361) N=797,8278 (6 to 10)10 (8 to 12)
SecondaryPercentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination

Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline8 (6 to 10)7 (6 to 9)
1 month post 1st vaccination (Day 31) N=931,9478 (6 to 10)8 (6 to 10)
1 month post 2nd vaccination (Day 61) N=916, 9289 (8 to 12)8 (6 to 10)
3 months post 2nd vaccination (Day 121) N=860, 8859 (7 to 11)9 (8 to 11)
5 months post 2nd vaccination (Day 181) N=832,8649 (7 to 11)9 (7 to 11)
11 months post 2nd vaccination (Day 361) N=797,8278 (6 to 10)9 (7 to 11)
SecondaryPercentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination

Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline1 (1 to 2)1 (1 to 2)
1 month post 1st vaccination (N=931,947)1 (0 to 2)1 (0 to 2)
1 month post 2nd vaccination (N=916,928)1 (1 to 2)2 (1 to 3)
3 months post 2nd vaccination (N=860,885)1 (0 to 2)1 (0 to 2)
5 months post 2nd vaccination (N=832,864)1 (0 to 2)1 (0 to 2)
11 months post 2nd vaccination (N=797,827)1 (0 to 1)1 (0 to 2)
SecondaryPercentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination

Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline33 (31 to 37)31 (28 to 34)
1 month post 1st vaccination (N=931, 947)34 (31 to 37)32 (29 to 35)
1 month post 2nd vaccination (N=916, 928)38 (35 to 41)36 (33 to 40)
3 months post 2nd vaccination (N=860, 885)35 (32 to 39)36 (33 to 39)
5 months post 2nd vaccination (N=832, 864)34 (30 to 37)36 (33 to 40)
11 months post 2nd vaccination (N=797, 827)27 (24 to 30)30 (27 to 34)
SecondaryPercentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination

Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline19 (17 to 22)17 (15 to 19)
1 month post 1st vaccination (N=931, 947)19 (17 to 22)19 (16 to 21)
1 month post 2nd vaccination (N=916, 928)22 (19 to 25)22 (19 to 24)
3 months post 2nd vaccination (N=860, 885)20 (17 to 23)22 (19 to 25)
5 months post 2nd vaccination (N=832, 864)19 (17 to 22)23 (20 to 26)
11 months post 2nd vaccination (N=797, 827)15 (12 to 17)18 (15 to 20)
SecondaryPercentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination

Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline10 (8 to 12)8 (7 to 10)
1 month post 1st vaccination (N=931, 947)11 (9 to 13)10 (8 to 12)
1 month post 2nd vaccination (N=916, 928)11 (9 to 13)12 (10 to 14)
3 months post 2nd vaccination (N=860, 885)10 (8 to 12)12 (10 to 14)
5 months post 2nd vaccination (N=832, 864)10 (8 to 12)13 (11 to 15)
11 months post 2nd vaccination (N=797, 827)7 (5 to 8)8 (6 to 10)
SecondaryPercentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination

Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline7 (6 to 9)5 (4 to 7)
1 month post 1st vaccination (N=931, 947)7 (5 to 9)6 (5 to 8)
1 month post 2nd vaccination (N=916, 928)7 (5 to 9)8 (6 to 10)
3 months post 2nd vaccination (N=860, 885)6 (5 to 8)8 (6 to 10)
5 months post 2nd vaccination (N=832, 864)6 (5 to 8)9 (7 to 11)
11 months post 2nd vaccination (N=797, 827)5 (4 to 7)5 (3 to 7)
SecondaryPercentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination

Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline7 (6 to 9)7 (5 to 9)
1 month post 1st vaccination (N=931, 947)9 (7 to 11)8 (7 to 10)
1 month post 2nd vaccination (N=916, 928)9 (7 to 11)10 (9 to 13)
3 months post 2nd vaccination (N=860, 885)8 (6 to 10)10 (8 to 12)
5 months post 2nd vaccination (N=832, 864)8 (7 to 10)10 (8 to 13)
11 months post 2nd vaccination (N=797, 827)5 (4 to 7)6 (5 to 8)
SecondaryPercentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination

Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline6 (4 to 7)5 (3 to 6)
1 month post 1st vaccination (N=931, 947)6 (4 to 8)5 (4 to 7)
1 month post 2nd vaccination (N=916, 928)5 (4 to 7)7 (6 to 9)
3 months post 2nd vaccination (N=860, 885)5 (4 to 7)7 (5 to 9)
5 months post 2nd vaccination (N=832, 864)6 (4 to 8)7 (6 to 9)
11 months post 2nd vaccination (N=797, 827)4 (3 to 6)4 (3 to 6)
SecondaryPercentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination

Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline9 (7 to 11)8 (7 to 10)
1 month post 1 dose (N=956, 947)10 (8 to 12)10 (8 to 12)
2 months post 1 dose (N=929, 928)9 (8 to 12)12 (10 to 14)
4 months post 1 dose (N=884, 885)10 (8 to 12)12 (10 to 14)
6 months post 1 dose (N=867, 864)11 (9 to 13)13 (11 to 15)
12 months post 1 dose (N=845, 827)8 (6 to 10)8 (6 to 10)
SecondaryPercentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination

Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline (Day 1)6 (5 to 8)5 (4 to 7)
1 month post 1 dose (N=956, 947)6 (5 to 8)6 (5 to 8)
2 months post 1 dose (N=929, 928)5 (4 to 7)8 (6 to 10)
4 months post 1 dose (N=884, 885)6 (5 to 8)8 (6 to 10)
6 months post 1 dose (N=867, 864)6 (5 to 8)9 (7 to 11)
12 months post 1 dose (N=845, 827)4 (3 to 6)5 (3 to 7)
SecondaryPercentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination

Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline7 (5 to 8)7 (5 to 9)
1 month post 1 dose (N=956, 947)7 (6 to 9)8 (7 to 10)
2 months post 1 dose (N=929, 928)7 (6 to 9)10 (9 to 13)
4 months post 1 dose (N=884, 885)8 (6 to 10)10 (8 to 12)
6 months post 1 dose (N=867, 864)9 (7 to 11)10 (8 to 13)
12 months post 1 dose (N=845, 827)6 (5 to 8)6 (5 to 8)
SecondaryPercentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination

Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline4 (3 to 6)5 (3 to 6)
1 month post 1 dose (N=956, 947)5 (4 to 6)5 (4 to 7)
2 months post 1 dose (N=929, 928)4 (3 to 5)7 (6 to 9)
4 months post 1 dose (N=884, 885)5 (4 to 7)7 (5 to 9)
6 months post 1 dose (N=867, 864)5 (4 to 7)7 (6 to 9)
12 months post 1 dose (N=845, 827)4 (3 to 5)4 (3 to 6)
SecondaryPercentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination

The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline non-carrier90 (87 to 92)91 (89 to 93)
1 month post 1st vaccination (N=671, 715)3 (2 to 5)4 (2 to 5)
1 month post 2nd vaccination (N=650, 687)3 (2 to 5)2 (1 to 3)
3 months post 2nd vaccination (N=628, 674)1 (0 to 2)3 (1 to 4)
5 months post 2nd vaccination (N=623, 656)1 (1 to 3)2 (1 to 4)
11 months post 2nd vaccination (N=614, 642)3 (2 to 5)3 (2 to 5)
At 3,5,11 months post 2nd vaccination (N=628,674)5 (4 to 7)7 (6 to 10)
SecondaryPercentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination

The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline non-carrier91 (89 to 93)92 (90 to 94)
1 month post 1st vaccination (N=682, 726)3 (2 to 5)3 (2 to 5)
1 month post 2nd vaccination (N=659, 699)3 (2 to 5)2 (1 to 3)
3 months post 2nd vaccination (N=638, 686)1 (0 to 2)2 (1 to 4)
5 months post 2nd vaccination (N=632, 670)1 (1 to 3)2 (1 to 3)
11 months post 2nd vaccination (N=623, 656)3 (2 to 5)2 (1 to 4)
At 3,5, 11 months post 2nd vaccination (N=638,686)5 (4 to 7)6 (5 to 9)
SecondaryPercentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination

The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline non-carrier77 (74 to 80)80 (77 to 83)
1 month post 1st vaccination (N=578, 627)17 (14 to 20)18 (15 to 21)
1 month post 2nd vaccination (N=479, 513)14 (11 to 18)12 (9 to 15)
3 months post 2nd vaccination (N=410, 452)9 (6 to 12)13 (10 to 16)
5 months post 2nd vaccination (N=374, 395)8 (5 to 11)9 (6 to 12)
11 months post 2nd vaccination (N=344, 361)11 (8 to 15)14 (10 to 18)
At 3,5, 11 months post 2nd vaccination (N=410,452)26 (21 to 30)31 (27 to 35)
SecondaryPercentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination

The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination
Percentages of subjectsrMenB+OMVControl
Baseline non-carrier82 (79 to 85)84 (82 to 87)
1 month post 1st vaccination (N=611, 663)9 (7 to 12)10 (8 to 13)
1 month post 2nd vaccination (N=553, 592)6 (4 to 8)7 (5 to 9)
3 months post 2nd vaccination (N=519, 551)4 (3 to 6)7 (5 to 9)
5 months post 2nd vaccination (N=497, 515)5 (3 to 7)5 (3 to 7)
11 months post 2nd vaccination (N=472, 491)6 (4 to 8)6 (4 to 9)
At 3,5, 11 months post 2nd vaccination (N=519,551)14 (11 to 18)17 (14 to 20)
SecondaryPercentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination

The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline non-carrier94 (92 to 96)95 (93 to 96)
1 month post 1st vaccination (N=746, 745)4 (3 to 6)5 (3 to 6)
1 month post 2nd vaccination (N=712, 709)2 (1 to 3)4 (3 to 6)
3 months post 2nd vaccination (N=701, 680)2 (1 to 4)3 (2 to 5)
5 months post 2nd vaccination (N=685, 660)3 (2 to 4)2 (1 to 3)
11 months post 2nd vaccination (N=666, 650)2 (1 to 3)1 (1 to 3)
1,3,5, 11 months post 2nd vaccination (N=712, 709)8 (6 to 11)10 (8 to 12)
SecondaryPercentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination

The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination
Percentages of subjectsMenACWYControl
Baseline non-carrier95 (94 to 97)95 (94 to 97)
1 month post 1st vaccination (N=758, 749)4 (2 to 5)4 (3 to 6)
1 month post 2nd vaccination (N=730, 719)1 (1 to 2)4 (2 to 5)
3 months post 2nd vaccination (N=719, 693)1 (1 to 3)2 (1 to 4)
5 months post 2nd vaccination (N=709, 678)2 (1 to 3)1 (1 to 3)
11 months post 2nd vaccination (N=694, 669)2 (1 to 3)1 (1 to 3)
1,3,5, 11 months post 2nd vaccination (N=730, 719)6 (5 to 8)8 (6 to 10)
SecondaryThe Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV

The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.

Time frame:
Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)
Reported as:
Least squares mean · Number of days
The Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV
Number of daysrMenB+OMVControl
Genogroup B All STs (N=152, 160)127 (92 to 162)146 (112 to 180)
Genogroup B virulent STs (N=142, 142)122 (87 to 157)147 (113 to 182)
All N meningitidis193 (176 to 210)202 (185 to 219)
Genogroups ABCWY (N=300, 323)143 (122 to 164)162 (141 to 183)
Serogroups ACWY (N=131, 142)104 (79 to 129)113 (87 to 138)
Serogroup Y (N=106, 123)106 (79 to 132)117 (91 to 144)
SecondaryThe Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM

The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.

Time frame:
Any time post vaccination (the date of first observation of the carriage and the date of the last observation of the carriage)
Reported as:
Least squares mean · Number of days
The Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM
Number of daysMenACWYControl
Serogroups ACWY88 (62 to 114)113 (87 to 138)
Serogroup Y (N=110, 123)86 (59 to 114)117 (91 to 144)
SecondaryThe Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine

The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.

Time frame:
Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)
Reported as:
Least squares mean · Number of days
The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine
Number of daysrMenB+OMVControl
Genogroup B All STs (N=76, 89)82 (44 to 120)107 (71 to 142)
Genogroup B virulent STs (N=77, 82)80 (42 to 117)107 (70 to 143)
All N meningitidis158 (135 to 181)165 (142 to 188)
Genogroups ABCWY (N=165, 201)121 (96 to 146)146 (122 to 170)
Serogroups ACWY (N=75, 102)111 (79 to 143)120 (89 to 151)
Serogroup Y (N=61, 87)111 (76 to 146)120 (87 to 153)
SecondaryThe Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine

The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.

Time frame:
Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)
Reported as:
Least squares mean · Number of days
The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine
Number of daysMenACWYControl
Serogroups ACWY90 (57 to 123)120 (89 to 151)
Serogroup Y (N=74, 87)87 (52 to 122)120 (87 to 153)
SecondaryPercentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination

The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported. The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA). H44/76, 5/99 and NZ98/254 are strains in serogroup B.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentage
Percentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination
PercentagerMenB+OMVControl
Baseline hSBA < 4 (H44/76) (N=60,19)0 (0 to 6)0 (0 to 18)
1month post 1st dose; hSBA<4(H44/76) (N=60, 18)3 (0 to 12)0 (0 to 19)
1month post 2nd dose; hSBA<4(H44/76) (N=60, 18)7 (2 to 16)0 (0 to 19)
3months post 2nd dose; hSBA<4(H44/76) (N=56, 17)4 (0 to 12)0 (0 to 20)
5 months post 2nd dose; hSBA <4(H44/76) (N=56, 17)7 (2 to 17)0 (0 to 20)
11 months post 2nd dose;hSBA <4(H44/76) (N=56, 16)11 (4 to 22)0 (0 to 21)
Baseline hSBA ≥4 (H44/76)10 (5 to 16)6 (1 to 21)
1month post 1st dose; hSBA ≥4 (H44/76) (N=130, 30)5 (2 to 11)10 (2 to 27)
1 month post 2nd dose;hSBA ≥4 (H44/76) (N=130, 30)8 (4 to 14)7 (1 to 22)
3 months post 2nd dose;hSBA ≥4 (H44/76) (N=120,29)9 (5 to 16)14 (4 to 32)
5 months post 2nd dose;hSBA ≥4 (H44/76) (N=115,28)5 (2 to 11)11 (2 to 28)
11 months post 2nd dose;hSBA ≥4 (H44/76)(N=123,30)5 (2 to 10)7 (1 to 22)
Baseline hSBA < 4 (5/99) (N=77, 23)5 (1 to 13)9 (1 to 28)
1month post 1st dose; hSBA<4 (5/99) (N=77, 22)4 (1 to 11)9 (1 to 29)
1 month post 2nd dose;hSBA <4 (5/99) (N=77, 22)6 (2 to 15)0 (0 to 15)
3 months post 2nd dose;hSBA <4 (5/99) (N=71, 21)4 (1 to 12)10 (1 to 30)
5 months post 2nd dose;hSBA <4 (5/99) (N=68, 21)3 (0 to 10)10 (1 to 30)
11 months post 2nd dose;hSBA <4(5/99) (N=71, 20)7 (2 to 16)5 (0 to 25)
Baseline hSBA ≥4 (5/99) (N=116, 27)8 (4 to 14)0 (0 to 13)
1month post 1st dose; hSBA ≥4 (5/99) (N=113, 26)5 (2 to 11)4 (0.097 to 20)
1 month post 2nd dose;hSBA ≥4 (5/99) (N=113, 26)8 (4 to 15)8 (1 to 25)
3 months post 2nd dose;hSBA ≥4 (5/99) (N=105, 25)10 (5 to 17)8 (1 to 26)
5 months post 2nd dose;hSBA ≥4 (5/99) (N=103, 24)8 (3 to 15)4 (0 to 21)
11 months post 2nd dose;hSBA ≥4(5/99) (N=108, 26)6 (3 to 13)4 (0.097 to 20)
Baseline hSBA < 4 (NZ98/254) (N=83, 31)2 (0 to 8)6 (1 to 21)
1month post 1st dose; hSBA<4(NZ98/254) (N=81, 30)4 (1 to 10)7 (1 to 22)
1month post 2nd dose; hSBA<4 (NZ98/254) (N=81, 30)4 (1 to 10)0 (0 to 12)
3 months post 2nd dose;hSBA <4 (NZ98/254)(N=75,29)3 (0 to 9)3 (0.087 to 18)
5 months post 2nd dose;hSBA <4 (NZ98/254)(N=70,29)3 (0 to 10)3 (0.087 to 18)
11 months post 2nd dose;hSBA <4(NZ98/254)(N=75,28)11 (5 to 20)4 (0.09 to 18)
Baseline hSBA ≥4 (NZ98/254) (N=110, 19)10 (5 to 17)0 (0 to 18)
1month post 1st dose; hSBA ≥4 (NZ98/254)(N=109,18)6 (2 to 12)6 (0 to 27)
1 month post 2nd dose;hSBA ≥4 (NZ98/254)(N=109,18)10 (5 to 17)11 (1 to 35)
3 months post 2nd dose;hSBA ≥4(NZ98/254)(N=101,17)11 (6 to 19)18 (4 to 43)
5 months post 2nd dose;hSBA ≥4(NZ98/254)(N=101,16)8 (3 to 15)13 (2 to 38)
11 months post 2nd dose;hSBA≥4(NZ98/254)(N=104,18)4 (1 to 10)6 (0 to 27)
SecondaryPercentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers

The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.

Time frame:
Up to 12 months after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers
Percentages of subjectsMenACWYControl
Baseline hSBA <8 (MenY) (N=42, 44)0 (0 to 8)0 (0 to 8)
1month post 1st dose; hSBA <8 (MenY) (N=39, 40)0 (0 to 9)3 (0.063 to 13)
1 month post 2nd dose;hSBA <8 (MenY) (N=39, 40)0 (0 to 9)0 (0 to 9)
3 months post 2nd dose;hSBA <8 (MenY) (N=36, 37)0 (0 to 10)3 (0.068 to 14)
5 months post 2nd dose;hSBA <8 (MenY) (N=36, 36)0 (0 to 10)6 (1 to 19)
11 months post 2nd dose;hSBA <8 (MenY) (N=34, 35)3 (0.074 to 15)6 (1 to 19)
Baseline hSBA ≥8 (MenY)6 (3 to 11)6 (3 to 11)
1month post 1st dose; hSBA ≥8 (MenY) (N=146,151)6 (3 to 11)5 (2 to 10)
1 month post 2nd dose;hSBA ≥8 (MenY) (N=143, 149)5 (2 to 10)5 (2 to 10)
3 months post 2nd dose;hSBA ≥8 (MenY) (N=131, 139)8 (4 to 14)7 (4 to 13)
5 months post 2nd dose;hSBA ≥8 (MenY) (N=130, 134)9 (5 to 16)5 (2 to 10)
11 months post 2nd dose;hSBA ≥8 (MenY) (N=129,135)4 (1 to 9)3 (1 to 7)
SecondaryPercentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group

The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group
Percentages of subjectsrMenB+OMVMenACWYControl
Baseline H44/7669 (62 to 75)71 (57 to 83)62 (47 to 75)
1 month post 2nd dose (H44/76) (N=189, 45, 48)100 (98 to 100)76 (60 to 87)63 (47 to 76)
3 months post 2nd dose (H44/76) (N=173, 40, 46)99 (97 to 100)73 (56 to 85)65 (50 to 79)
5 months post 2nd dose (H44/76) (N=169, 43, 45)100 (98 to 100)74 (59 to 86)67 (51 to 80)
11 months post 2nd dose (H44/76) (N=177, 41, 46)95 (91 to 98)76 (60 to 88)70 (54 to 82)
Baseline 5/9960 (53 to 67)45 (31 to 60)54 (39 to 68)
1 month post 2nd dose (5/99) (N=189, 45, 48)100 (98 to 100)40 (26 to 56)58 (43 to 72)
3 months post 2nd dose (5/99) (N=173, 40, 46)99 (97 to 100)49 (33 to 65)53 (38 to 68)
5 months post 2nd dose (5/99) (N=169, 43, 45)99 (97 to 100)49 (33 to 65)53 (38 to 68)
11 months post 2nd dose (5/99) (N=177, 41, 46)97 (94 to 99)51 (35 to 67)63 (48 to 77)
Baseline NZ98/25457 (50 to 64)53 (38 to 67)38 (25 to 53)
1 month post 2nd dose (NZ98/254) (N=189, 45, 48)99 (97 to 100)53 (38 to 68)44 (29 to 59)
3 months post 2nd dose (NZ98/254) (N=173, 40, 46)93 (88 to 96)48 (32 to 64)48 (33 to 63)
5 months post 2nd dose (NZ98/254) (N=169, 43, 45)91 (85 to 94)58 (42 to 73)42 (28 to 58)
11 months post 2nd dose (NZ98/254) (N=177, 41, 46)85 (79 to 90)66 (49 to 80)43 (29 to 59)
SecondaryThe hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.

The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.

Time frame:
Up to 361 days after vaccination
Reported as:
Geometric mean · Titers
The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.
TitersrMenB+OMVMenACWYControl
Baseline H44/7611 (8.74 to 14)11 (6.59 to 18)9.42 (5.73 to 15)
1 month post 2nd dose (H44/76) (N=189, 45, 48)229 (192 to 274)11 (7.92 to 16)10 (7.18 to 15)
3 months post 2nd dose (H44/76) (N=173, 40, 46)144 (116 to 178)9.07 (5.79 to 14)11 (7.07 to 16)
5 months post 2nd dose (H44/76) (N=169, 43, 45)111 (89 to 138)12 (7.57 to 18)12 (7.62 to 18)
11 months post 2nd dose (H44/76) (N=177, 40, 46)68 (54 to 84)14 (8.84 to 22)14 (8.97 to 21)
Baseline 5/996.44 (5.1 to 8.13)3.12 (1.97 to 4.95)5.49 (3.47 to 8.67)
1 month post 2nd dose (5/99) (N=189, 45, 48)424 (355 to 507)2.63 (1.83 to 3.79)5.62 (3.95 to 8.01)
3 months post 2nd dose (5/99) (N=173, 40, 46)169 (139 to 207)2.95 (1.94 to 4.47)5.6 (3.8 to 8.26)
5 months post 2nd dose (5/99) (N=169, 43, 45)105 (87 to 128)3.36 (2.27 to 4.97)5.32 (3.63 to 7.79)
11 months post 2nd dose (5/99) (N=177, 41, 46)55 (45 to 67)3.58 (2.37 to 5.4)5.98 (4.05 to 8.82)
Baseline NZ98/2546.15 (4.82 to 7.84)4.32 (2.66 to 7)4.16 (2.58 to 6.72)
1 month post 2nd dose (NZ98/254) (N=188, 45, 48)99 (80 to 122)4.82 (3.11 to 7.47)3.88 (2.54 to 5.93)
3 months post 2nd dose (NZ98/254) (N=172, 40, 46)56 (44 to 73)4.93 (2.89 to 8.4)4.72 (2.87 to 7.76)
5 months post 2nd dose (NZ98/254) (N=169, 43, 45)50 (38 to 66)6.5 (3.73 to 11)4.67 (2.72 to 8.03)
11 months post 2nd dose (NZ98/254) (N=176, 41, 44)34 (26 to 45)7.77 (4.38 to 14)6.93 (3.99 to 12)
SecondaryPercentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.

The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.
Percentages of subjectsrMenB+OMVMenACWYControl
Baseline Men C (N= 49, 194,50)90 (78 to 97)87 (81 to 91)80 (66 to 90)
1 month post 2nd dose (Men C) (N=48, 182, 48)98 (89 to 100)99 (96 to 100)88 (75 to 95)
11 months post 2nd dose (Men C) (N=48, 158, 41)94 (83 to 99)97 (93 to 99)88 (74 to 96)
Baseline Men Y72 (65 to 78)78 (72 to 84)78 (71 to 83)
1 month post 2nd dose (Men Y) (N=187, 182, 188)81 (74 to 86)95 (90 to 97)82 (76 to 88)
3 months post 2nd dose (Men Y) (N=173,164,175)79 (72 to 85)95 (90 to 97)82 (75 to 87)
5 months post 2nd dose (Men Y) (N=170, 165, 170)78 (71 to 84)92 (87 to 96)84 (77 to 89)
11 months post 2nd dose (Men Y) (N=177, 158, 165)77 (71 to 83)91 (86 to 95)81 (74 to 87)
SecondaryThe hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.

The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs. Serogroups A and W were not analysed.

Time frame:
Up to 361 days after vaccination
Reported as:
Geometric mean · Titers
The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.
TitersrMenB+OMVMenACWYControl
Baseline Men C (N=49, 194, 50)43 (26 to 70)50 (39 to 65)32 (20 to 53)
1 month post 2nd dose (Men C) (N=48, 182, 48)83 (55 to 126)1302 (1050 to 1615)37 (24 to 56)
11 months post 2nd dose (MenC) (N=48, 158, 41)59 (38 to 91)438 (343 to 560)41 (25 to 66)
Baseline Men Y18 (14 to 22)19 (15 to 23)19 (15 to 23)
1 month post 2nd dose (Men Y) (N=187, 182, 188)26 (21 to 32)83 (67 to 103)23 (18 to 28)
3 months post 2nd dose (Men Y) (N=173, 164, 175)24 (19 to 30)69 (56 to 86)22 (17 to 27)
5 months post 2nd dose (Men Y (N=170, 165, 170)23 (19 to 29)63 (51 to 78)22 (18 to 28)
11 months post 2nd dose (Men Y) (N=177, 158, 165)21 (17 to 26)49 (39 to 61)22 (17 to 27)
SecondaryPercentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.

The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported. Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer \< 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer. Analysis was not done for serogroups A and W.

Time frame:
61 days
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.
Percentages of subjectsrMenB+OMVMenACWYControl
1 month post 2nd dose from day 1(Men C)N=48,181,488 (2 to 20)81 (75 to 87)4 (1 to 14)
1 month post 2nd dose from day 1(Men Y)12 (8 to 17)44 (37 to 52)7 (4 to 12)
SecondaryThe hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group

The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. Analysis was not done for serogroups A and W.

Time frame:
Up to 361 days after vaccination
Reported as:
Geometric mean · Titers
The hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group
TitersMenACWYControl
Baseline (Men C) (N=46, 6)91 (51 to 160)157 (33 to 756)
1 month post 2nd vaccination (Men C) (N=45, 6)1905 (1305 to 2779)154 (55 to 434)
11 months post 2nd vaccination (Men C) (N=45, 6)691 (464 to 1028)125 (42 to 371)
Baseline (Men Y)21 (13 to 32)23 (13 to 41)
1 month post 2nd vaccination (Men Y) (N=45, 26)89 (55 to 142)19 (10 to 36)
3 months post 2nd vaccination (Men Y) (N=42, 25)67 (41 to 110)20 (11 to 38)
5 months post 2nd vaccination (Men Y) (N=45, 26)65 (41 to 103)20 (11 to 37)
11 months post 2nd vaccination (Men Y) (N=45, 26)48 (31 to 76)22 (12 to 39)
SecondaryPercentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.

The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported. Analysis was not done for serogroups A and W.

Time frame:
Up to 361 days after vaccination
Reported as:
Number · Percentages of subjects
Percentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.
Percentages of subjectsMenACWYControl
Baseline (Men C) (N=46,6)93 (82 to 99)100 (54 to 100)
1 month post 2nd vaccination (Men C) (N=45, 6)100 (92 to 100)100 (54 to 100)
11 months post 2nd vaccination (Men C) (N=45, 6)100 (92 to 100)100 (54 to 100)
Baseline (Men Y)80 (66 to 91)81 (61 to 93)
1 month post 2nd vaccination (Men Y) (N=45, 26)96 (85 to 99)77 (56 to 91)
3 months post 2nd vaccination (Men Y) (N=42, 25)95 (84 to 99)80 (59 to 93)
5 months post 2nd vaccination (Men Y) (N=45, 26)96 (85 to 99)77 (56 to 91)
11 months post 2nd vaccination (Men Y) (N=45, 26)91 (79 to 98)77 (56 to 91)
SecondaryNumber of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group

The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.

Time frame:
Day 1 through day 7 after any vaccination
Reported as:
Number · number of subjects
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group
number of subjectsrMenB+OMVMenACWYControl
Any local184158139
Injection site pain (N=190, 186,191)181143117
Injection site erythema (N=190, 186, 191)1007161
Injection site induration (N=190, 186, 191)684121
Injection site swelling (N=190, 186, 191)683123
Any systemic169133140
Arthralgia (N=190, 186, 191)382729
Nausea (N=190, 186, 191)362324
Malaise (N=190, 186, 191)574146
Myalgia (N=190, 186, 191)155117112
Headache (N=190, 186, 191)715675
Rash (N=190, 186, 191)9912
Fever (≥38°C) (N= 190, 186,191)757
Any Other642225
Temperature (≥40°C) (N= 190, 186, 191)000
Antipyretic preventive med. used (N=190, 186, 191)2073
Antipyretic treatment med. used (N=190, 186, 191)551722

Adverse events

Collected over Solicited adverse events were collected from Day1 to day 7 post vaccination; unsolicited AEs were collected throughout the study period (Day 1-Day 361). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB+OMV—31/974 (3.2%)200/974 (20.5%)
MenACWY—26/984 (2.6%)186/984 (18.9%)
Control—20/985 (2%)172/985 (17.5%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventrMenB+OMVMenACWYControl
PyelonephritisInfections and infestations3/9740/9840/985
Abdominal painGastrointestinal disorders1/9743/9840/985
AppendicitisInfections and infestations1/9743/9841/985
TonsillitisInfections and infestations2/9740/9840/985
Urinary tract infectionInfections and infestations2/9740/9840/985
Pilonidal cystInfections and infestations0/9742/9840/985
CoughRespiratory, thoracic and mediastinal disorders0/9742/9840/985
Thyroiditis acuteEndocrine disorders1/9740/9840/985
Edema peripheralGeneral disorders1/9740/9840/985
Anaphylactic reactionImmune system disorders1/9741/9840/985
Most frequent other events
Most frequent other events
EventrMenB+OMVMenACWYControl
Injection site painGeneral disorders182/974145/984117/985
MyalgiaMusculoskeletal and connective tissue disorders155/974119/984112/985
Injection site erythemaGeneral disorders102/97471/98461/985
HeadacheNervous system disorders82/97467/98485/985
Injection site indurationGeneral disorders68/97442/98421/985
Injection site swellingGeneral disorders68/97432/98423/985
MalaiseGeneral disorders58/97443/98447/985

Baseline characteristics

Age, Continuous
Age, Continuous(years)rMenB+OMVMenACWYControlTotal
Mean19.9 ± 1.619.9 ± 1.619.8 ± 1.619.9 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)rMenB+OMVMenACWYControlTotal
Female5165335471596
Male4634554401358
08

Study locations

10 sites
  • Clinical Research Center, University of Surrey
    Surrey, England, United Kingdom
  • Bristol Children's Vaccine Center, University of Bristol,
    Bristol, England, United Kingdom
  • Royal Liverpool and Broad Green University Hospital Trust
    Liverpool, England, United Kingdom
  • St Georges Vaccine Institute, St Georges, University of London
    London, England, United Kingdom
  • Manchester Welcome Trust Clinical Research Facility, University of Manchester
    Manchester, England, United Kingdom
  • The James Cook University Hospital
    Middlesbrough, England, United Kingdom
  • Cripps Health Centre, University Park
    Nottingham, England, United Kingdom
  • University of Oxford, Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine
    Oxford, England, United Kingdom
  • Clinical Research Facility, Royal Hallamshire Hospital
    Sheffield, England, United Kingdom
  • Wellcome Trust Clinical Research Facility, University of Southampton
    Southampton, England, United Kingdom
09

References and documents

Publications

  • Lemee L, Hong E, Etienne M, Deghmane AE, Delbos V, Terrade A, Berthelot G, Caron F, Taha MK. Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis. PLoS One. 2014 Sep 23;9(9):e107240. doi: 10.1371/journal.pone.0107240. eCollection 2014. PubMed 25247300 ↗
  • Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014 Dec 13;384(9960):2123-31. doi: 10.1016/S0140-6736(14)60842-4. Epub 2014 Aug 18. PubMed 25145775 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 2 years after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2010
First posted
Oct 5, 2010
Start
Sep 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results delay requested
Dec 11, 2012
Results first posted
Jan 23, 2014
Last update
Apr 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01214850
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Oct 5, 2010
Start date
Sep 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jan 23, 2014
Last update
Apr 21, 2016

Study contacts

Novartis Vaccines and Diagnostics
study chair · Novartis Vaccines
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion